TY  - JOUR
T1  - Platelet-Rich Plasma: The Next Big Thing?Commentary on an article by Ujash Sheth, BHSc, et al.: “Efficacy of Autologous Platelet-Rich Plasma Use for Orthopaedic Indications: A Meta-Analysis”
AU  - Matava, Matthew J.
Y1  - 2012/02/15
N1  - 10.2106/JBJS.K.01423
JO  - The Journal of Bone & Joint Surgery
SP  - e25 1
EP  - 2
VL  - 94
IS  - 4
N2  - 
Autologous blood concentrates, one of which is platelet-rich plasma, have been becoming more popular as a result of the increasing attention that these products have received in the mainstream media following their use by high-profile athletes. Platelet-rich plasma has been utilized for a number of musculoskeletal conditions despite a relative lack of rigorous supportive data. Thus, there is a growing debate regarding the clinical efficacy of this treatment regimen. Several uncontrolled studies have shown beneficial effects for a variety of indications. However, the results of controlled trials comparing platelet-rich plasma with standard therapies have not been as definitive. Despite this relative lack of robust evidence, the market for platelet-rich plasma is expected to be worth $126 million by 20161.

SN  - 0021-9355
M3  - doi: 10.2106/JBJS.K.01423
UR  - http://dx.doi.org/10.2106/JBJS.K.01423
ER  -